In Vitro Investigations on Some Components of the Kinin System (Kininogen, Serum Kallikrein, Hageman Factor), and Their Interaction

  • R. Jahrreiss
  • E. Habermann
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 8)


During the past years, knowledge has been accumulated concerning the components of the plasma kinin system and their interactions. Various workers described different kininogenases or kininogens, and some found evidences for distinct functions of such components present even in the same plasma. This led to the assumption of at least two kinin-forming systems in one plasma. In addition, there exists no agreement about the physicochemical and enzymatic properties of Hageman factor. It was tempting to consider the occurrence of more than one kind of contact factors.


Bovine Plasma Plasma Kallikrein Kinin System Substrate Function Hageman Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1).
    DINIZ, C.R., J.F. CARVALHO, J. Ryan a. M. Rocha e Silva: Nature 192, 1194 (1961).PubMedCrossRefGoogle Scholar
  2. 2).
    HABERMANN, E.: Biochem.Z. 337, 440 (1963).PubMedGoogle Scholar
  3. 3).
    HABERMANN, E.: Arch.exp.Path. Pharmak. 253, 474 (1966).Google Scholar
  4. 4).
    HABERMANN, E.: Ann.N.Y.Acad. Sci. 146, 479 (1968).PubMedCrossRefGoogle Scholar
  5. 5).
    HABERMANN, E., u. J. HELBIG: Arch.Pharmak.exp.Path. 258, 160 (1967).Google Scholar
  6. 6).
    HABERMANN, E., u. W. Klett: Biochem.Z. 346, 133 (1966).PubMedGoogle Scholar
  7. 7).
    HABERMANN, E., W. KLETT u. G. ROSENBUSCH: Z.physiol.Chem. 322, 121 (1963).CrossRefGoogle Scholar
  8. 8).
    HORTON, B.W.: J.Physiol. 142, 36P (1958).Google Scholar
  9. 9).
    JAHRREISS, R., u. E. HABERMàNN: Arch.Pharmak.exp.Path. 264, 172 (1969).Google Scholar
  10. 10).
    JOHNSTON, C.L., a. E.S. BARROW: Scand.J.Clin.Lab.Invest. 17, (Suppl. 84), 52 (1965).PubMedGoogle Scholar
  11. 11).
    MARGOLIS, J.: J.Physiol. 144, 1 (1958).PubMedGoogle Scholar
  12. 12).
    NAGASAWA, S., H. TAKAHASHI, M. KOIDA, T. SUZUKI a. J.G.G. Schoenmakers: Biochem.Biophys.Res.Comm. 32, 644 (1968).PubMedCrossRefGoogle Scholar
  13. 13).
    SCHOENMAKERS, J.G.G., R. MATZE, C. HAANEN a. F. ZILLIKEN: Biochim.biophys.Acta 101, 166 (1965).PubMedGoogle Scholar
  14. 14).
    SCHWERT, G.W., a. Y. TAKENAKA: Biochim.biophys.Acta l6, 570 (1955).CrossRefGoogle Scholar
  15. 15).
    SUZUKI, T., S. IWANAGA, S. NAGASAWA A. T. SATO: In: E.G. Erdös, N. Back, F. Sicuteri (Eds.): Hypotensive peptides, p. 149. Berlin-Heidelberg-New York: Springer 1966.Google Scholar
  16. 16).
    TEMME, H., R. JAHRREISS, E. HABERMANN u. F. ZILLIKEN: Z.physiol.Chem. 350, 519 (1969).Google Scholar
  17. 17).
    VOGT, W., G. GARBE u. G. SCHMIDT: Arch.Pharmak.exp.Path. 256, 127 (1967).Google Scholar
  18. 18).
    WEBSTER, M.E., a. O.D. Ratnoff: Nature 192, 180 (1961).PubMedCrossRefGoogle Scholar
  19. 19).
    YANO, M., S. NAGASAWA, K. HORIUCHI a. T. SUZUKI: J.Biochem. (Jap.) 62, 504 (1967).Google Scholar

Copyright information

© Plenum Press, New York 1970

Authors and Affiliations

  • R. Jahrreiss
    • 1
  • E. Habermann
    • 1
  1. 1.Pharmacological Institute63 GiessenGermany

Personalised recommendations